Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-7254
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease ; day:27 ; month:7 ; year:2022 ; pages:1-12
Acta pharmacologica Sinica ; (27.7.2022), 1-12
- Urheber
-
Dong, An-qi
Yang, Ya-ping
Jiang, Shu-min
Yao, Xiao-yu
Qi, Di
Mao, Cheng-jie
Cheng, Xiao-yu
Wang, Fen
Hu, Li-fang
Liu, Chun-feng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41401-022-00951-1
- URN
-
urn:nbn:de:101:1-2022100820582644971634
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dong, An-qi
- Yang, Ya-ping
- Jiang, Shu-min
- Yao, Xiao-yu
- Qi, Di
- Mao, Cheng-jie
- Cheng, Xiao-yu
- Wang, Fen
- Hu, Li-fang
- Liu, Chun-feng
- SpringerLink (Online service)
Ähnliche Objekte (12)
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3
TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson’s Disease Mice and LPS-Induced BV2 Cells
The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson’s disease via the microglial NLRP3 inflammasome
lincRNA-Cox2 regulates NLRP3 inflammasome and autophagy mediated neuroinflammation
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients
Dysregulation of autophagy and mitochondrial function in Parkinson’s disease
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3
TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson’s Disease Mice and LPS-Induced BV2 Cells
The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson’s disease via the microglial NLRP3 inflammasome
lincRNA-Cox2 regulates NLRP3 inflammasome and autophagy mediated neuroinflammation
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients
Dysregulation of autophagy and mitochondrial function in Parkinson’s disease
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3
TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson’s Disease Mice and LPS-Induced BV2 Cells
The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson’s disease via the microglial NLRP3 inflammasome
lincRNA-Cox2 regulates NLRP3 inflammasome and autophagy mediated neuroinflammation
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients
Dysregulation of autophagy and mitochondrial function in Parkinson’s disease